| metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) | metastatic/advanced RCC (mRCC) - 1st line (L1) | metastatic/advanced RCC (mRCC) - 2nd line (L2) | |||
| metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) | metastatic/advanced RCC (mRCC) - 1st line (L1) | mRCC - L1 - PDL1 negative | mRCC - L1 - PDL1 positive | metastatic/advanced RCC (mRCC) - 2nd line (L2) | |
| anti-PD-(L)1 | |||||
| atezolizumab based treatment | |||||
| atezolizumab alone | IMmotion-010 | IMmotion-150 ... | IMmotion-150 ... | ||
| atezolizumab plus bevacizumab | IMmotion-150 ... IMmotion-151 ... | IMmotion-151 ... | IMmotion-150 ... IMmotion-151 ... | ||
| atezolizumab plus cabozantinib | CONTACT-03 | ||||
| avelumab based treatment | |||||
| avelumab plus axitinib | JAVELIN Renal 101 ... | JAVELIN Renal 101... | |||
| nivolumab based treatment | |||||
| nivolumab alone | CheckMate 914 | CheckMate 025 | |||
| nivolumab plus cabozantinib | CheckMate 9ER | ||||
| pembrolizumab based treatment | |||||
| pembrolizumab alone | KEYNOTE-564 | ||||
| pembrolizumab plus axitinib | KEYNOTE-426 | ||||
| pembrolizumab plus lenvatinib | KEYNOTE-581/CLEAR ... | ||||
Study type:
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
